Introduction
============

Obesity is a fast growing epidemic worldwide and is closely associated with morbid conditions including diabetes, cardiovascular and respiratory diseases as well as cancer \[[@B1]\]. Approximately 65% of the United States population is overweight and 30% are obese. Obesity is increasingly a major health hazard in many developed and developing nations as well \[[@B2]-[@B4]\]. As a result, the proportion of obese patients admitted to hospitals is steadily increasing with an estimated cost that exceeds 5% of the national health expenditure in the US \[[@B2],[@B3]\]. Therefore, obesity became the target for national-level endeavors as evidenced by the most recent release of the Institute of Medicine recommendations to \'Solve the Weight of the Nation\' \[[@B5]\].

The prevalence of obese patients admitted to ICUs is also rising rapidly and poses complex challenges \[[@B6],[@B7]\]. However, intriguingly, despite the increased morbidity and the difficulty of administering standard care, data on outcome, although conflicting, are showing predominantly either equal or lower mortality in obese than in normal weight critically ill patients, while only a few reported higher mortality \[[@B8],[@B9]\]. A comparable phenomenon was also observed in obese patients with heart failure and is referred to as the \'obesity paradox\' \[[@B10]\]. Although an explanation of this paradox is not immediately clear, most of the studies have included either a heterogeneous population of obese critically ill patients or have failed to adjust for major confounding factors, such as sepsis interventions \[[@B11],[@B12]\]. The influence of obesity on specific ICU populations, such as patients with sepsis, has been the subject of much speculation but very few clinical data exist on this topic.

Sepsis is a major cause of morbidity and mortality worldwide and a leading admission diagnosis to ICUs \[[@B13]\] with substantial cost and considerable long-term health-related consequences \[[@B14]-[@B16]\]. Data on the impact of obesity on septic shock are primarily based on experimental and small clinical studies \[[@B17],[@B18]\].

Therefore, we sought to examine the association of obesity, assessed by body mass index (BMI), and hospital mortality in patients admitted with septic shock. We further assessed the differences in clinical and microbiologic features as well as septic shock-related interventions in association with obesity.

Materials and methods
=====================

Subjects and setting
--------------------

This was a retrospective cohort study from a large database of patients admitted with septic shock to the ICUs in 28 medical centers in Canada, United States, and Saudi Arabia by the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group between 1996 and 2008. The study protocol was approved by the Instititutional Review Board of the University of Manitoba, Winnipeg, Canada; the University of Toronto, Toronto, Canada; McGill University, Montreal, Canada; the University of British Columbia, Vancouver, Canada; Rush University, Chicago, IL, USA; Brandon Hospital, Brandon, Canada; St. Agnes Hospital, Baltimore, MD, USA; Harper Hospital, Detroit, MI, USA; Northern Medical School, Laurentian University, Sudbury, Canada; the University of Calgary, Calgary, Canada; the University of Wisconsin, Madison, WI, USA; Cooper Hospital/University Medical Center, Camden, NJ, USA; Vancouver Island Regional Health Authority, Victoria, Canada; Hospital Maissoneuve-Rosemont, Montreal, Canada; and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Informed consent was waived.

The original study included adult patients with septic shock defined according to the 1992 American College of Chest Physicians/Society of Critical Care Medicine guidelines \[[@B19]\]. The details regarding the full definitions used in the study have already been described \[[@B20],[@B21]\]. Patients with weight and height documented in the medical records on admission were included in this study.

Definition of obesity
---------------------

Obesity was defined using the World Health Organization (WHO) criteria according to BMI (calculated as weight in kilograms divided by the square of the height in meters (kg/m^2^)) \[[@B22]\]. Patients were classified as underweight (BMI \< 18.50 kg/m^2^), normal weight (BMI = 18.50 to 24.99 kg/m^2^), overweight (BMI = 25.0 to 29.99 kg/m^2^), obese (BMI = 30.0 to 39.99 kg/m^2^) or very obese (BMI \> 40 kg/m^2^).

Clinical characteristics and sepsis interventions
-------------------------------------------------

At baseline the following data were collected: age, gender, use of mechanical ventilation, Acute Physiology and Chronic Health Evaluation (APACHE) II score \[[@B23]\], admission physiologic data and comorbid conditions (immunosuppressive disorders, liver failure, heart failure, chronic obstructive pulmonary disease (COPD), chronic renal failure and medication- and insulin-dependent diabetes, alcohol abuse, elective and emergency surgery), laboratory data, organ failure indicators on admission \[see Additional file [1](#S1){ref-type="supplementary-material"}, Appendix A\], source of infection (community versus nosocomial infection), the presence of bacteremia, site of infection and microbiological data. We calculated creatinine clearance using the modification of diet in renal disease (MDRD) \[[@B24]\] and Cockcroft-Gault equations \[[@B25]\] \[see Additional file [1](#S1){ref-type="supplementary-material"}, Appendix B\]; the former was used in the multivariate analysis as it has been shown to perform better than Cockcroft-Gault equation in patients with extreme weights \[[@B26]\]. We calculated ideal and adjusted body weights and dosing weights for antimicrobials as recommended \[[@B6],[@B27]\] \[see Additional file [1](#S1){ref-type="supplementary-material"}, Appendix B\].

We documented the following data regarding sepsis interventions: the volume of crystalloids, colloids, and blood products administered during the first six hours of septic shock (in ml and in ml/kg of actual body weight). We also recorded the selection and doses of vasopressors, use of activated protein C and low-dose steroids. The following data were collected about antimicrobial therapy: appropriateness, delay in hours from the onset of hypotension and the use of single versus combination antimicrobial therapy. Detailed definitions of these variables have already been described \[[@B20],[@B21],[@B28]\]. We also documented the type and dose (total and dose per kg of dosing body weight) of antimicrobials administered on the first day.

Outcomes
--------

Hospital mortality was the primary outcome. Secondary outcomes were ICU mortality and ICU and hospital length of stay (LOS).

Statistical analysis
--------------------

Continuous variables are reported as means with standard deviations (SD) and categorical variables as absolute and relative frequencies. Analysis of variance (ANOVA) and chi-square tests for comparison among groups were used as appropriate.

To study the association between obesity and hospital mortality, we carried out multivariate logistic regression analyses with the normal weight group as reference. We assessed the association of different BMI groups and mortality in crude and multivariate models adjusting for covariates that were selected based on clinical relevance or statistical criteria (*P*value of 0.25 for inclusion and *P*value of 0.05 for retaining in the model). We first adjusted to baseline characteristics (model 1) including age, gender, mechanical ventilation, APACHE II score, chronic co-morbidities (immunosuppressive disorders, heart failure, COPD, and medication- and insulin-dependent diabetes, elective surgery), nosocomial versus community acquired infection, bacteremia, Gram-negative organisms, fungal organisms, anaerobes (with Gram-positive organisms used as reference), pneumonia, urinary tract infection, primary bloodstream infection, catheter-related bloodstream infection, skin and soft tissue infection, creatinine clearance as calculated by MDRD and country. To adjust for the impact of potential changes in practice over time, we divided the study time period into four quartiles and we included the study period in the multivariate model. In the second model (model 2) we added the following variables related to sepsis interventions: inappropriate antimicrobial therapy, single versus combination antimicrobial therapy, delayed antimicrobial therapy \> 3 hours, vasopressor doses (dopamine, norepinephrine, phenylephrine, epinephrine, and dobutamine), the use of a pulmonary artery catheter, activated protein C and the use of low-dose steroids. Among the variables included in the multivariate models, 3% of patients had missing values for APACHE II score and 3.5% of patients had missing data for MDRD, which were replaced by the means. Results were reported as odds ratios (ORs) with 95%CIs.

To study the association between BMI and the amount of fluid and antimicrobial dosage, we carried out multivariate linear regression analyses. We reported *P*values for the crude analysis and adjusted analysis for creatinine clearance. For the association of fluids and BMI, we also adjusted for pulmonary capillary wedge pressure in patients with a pulmonary artery catheter. A *P*value of \< 0.05 was considered significant. SAS (SAS Institute, Cary, NC, USA) software was used for statistical analyses.

Results
=======

Baseline characteristics
------------------------

Of the 8,670 patients included during the study period, 2,882 (33.2%) had height and weight documented. When compared to excluded patients who did not have documented values of both weight and height in the medical records, there were no differences in age (*P*= 0.07), APACHE II score (*P*= 0.10) and use of mechanical ventilation (*P*= 0.29). However, excluded patients were more likely to have comorbid conditions (*P*= 0.007) and had lower hospital mortality compared to the included patients (*P*= 0.03).

Overall, 35.3% of the study population was in the normal weight group, 6.8% were underweight, 28.3% overweight, 23.6% obese and 5.4% very obese. Table [1](#T1){ref-type="table"} shows their baseline characteristics. Compared with the reference group (normal weight), very obese and underweight patients were younger. Obese and very obese patients were less likely to have immunosuppressive disorders and more likely to have heart failure and diabetes mellitus compared to those with normal BMI. With increasing BMI, admission heart rate, temperature and mean arterial pressure were higher and respiratory rate was lower. Creatinine was higher and platelet count lower with increasing BMI with the corresponding organ failure indicators following the same pattern (Table [1](#T1){ref-type="table"}).

###### 

Baseline characteristics among different groups of BMI

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                            \< 18.50\       18.50 to 24.99\   25.0 to 29.99\   30.0 to -39.99\   ≥ 40\           *P*value
                                                       Number = 196    Number = 1,020    Number = 816     Number = 680      Number = 170    
  ---------------------------------------------------- --------------- ----------------- ---------------- ----------------- --------------- ----------
  Age (years), mean (SD)                               59.1 (19.2)     62.2 (16.8)       63.5 (15.9)      62.2 (14.6)       58.4 (13.0)     \< 0.001

  Gender, female, number (%)                           82 (41.8)       390 (38.2)        316 (38.7)       334 (49.1)        102 (60.0)      \< 0.001

  Actual body weight (kg), mean (SD)                   47.3 (7.1)      63.4 (10.2)       77.3 (10.1)      93.4 (14.7)       128.9 (28.1)    \< 0.001

  Ideal body weight (kg), mean (SD)                    61.7 (10.9)     62.9 (11.5)       62.4 (10.7)      60.4 (12.0)       58.3 (13.4)     \< 0.001

  Dosing body weight (kg), mean (SD)                   58.1 (9.7)      63.0 (10.9)       66.1 (10.4)      68.6 (12.3)       75.9 (15.8)     \< 0.001

  Height (cms), mean (SD)                              167.3 (10.6)    168.8 (11.1)      167.9 (10.1)     166.3 (11.5)      164.5 (13.3)    \< 0.001

  BMI (kg/m^2^), mean (SD)                             16.8 (1.3)      22.2 (1.8)        27.3 (1.4)       33.6 (2.7)        47.4 (7.4)      \< 0.001

  Mechanical ventilation, number (%)                   146 (74.5)      777 (76.2)        605 (74.1)       491 (72.2)        128 (75.3)      0.48

  APACHE II, mean (SD)                                 25.5 (8.0)      25.7 (8.1)        25.6 (8.4)       25.4 (7.9)        24.4(7.3)       0.43

  Admission physiologic data, mean (SD)                                                                                                     

   Heart rate (beats/minute)                           120.9 (30.3)    119.2 (29.4)      116.7 (29.9)     119.1 (29.5)      112.2 (31.0)    0.02

   Respiratory rate (beats/minute)                     29.0 (8.8)      27.0 (10.2)       26.6 (10.4)      26.0 (10.0)       25.8 (9.1)      0.005

   Temperature (°C)                                    37.2 (1.8)      37.5 (1.7)        37.7 (1.7)       37.8 (1.6)        37.8 (1.7)      \< 0.001

   Mean arterial pressure (mmHg)                       53.3 (13.3)     56.6 (16.5)       58.0 (19.0)      60.3 (20.1)       62.6 (22.2)     \< 0.001

  Co-morbidities, number (%)                                                                                                                

   Immunosuppressive disorder                          56 (28.6)       300 (29.4)        213 (26.1)       188 (27.7)        32 (18.8)       0.06

   Liver failure                                       14 (7.1)        91 (8.9)          67 (8.2)         53 (7.8)          19 (11.2)       0.59

   New York Heart Association class IV heart failure   16 (8.2)        70 (6.9)          95 (11.6)        77 (11.3)         21 (12.4)       0.002

   Severe COPD (requiring medication or oxygen)        22 (11.2)       102 (10.0)        88 (10.8)        83 (12.2)         32 (18.8)       0.02

   Chronic renal failure^a^                            35 (17.9)       155 (15.2)        126 (15.4)       100 (14.7)        34 (20.0)       0.43

   Chronic renal failure-dialysis dependence           17 (8.7)        81 (7.9)          45 (5.5)         41 (6.0)          12 (7.1)        0.20

   Diabetes mellitus (medication dependent)            10 (5.1)        127 (12.5)        141 (17.3)       159 (23.4)        45 (26.5)       \< 0.001

   Diabetes mellitus (insulin-dependent)               11 (5.6)        76 (7.5)          82 (10.1)        80 (11.8)         35 (20.6)       \< 0.001

   Alcohol abuse                                       29 (14.8)       162 (15.9)        107 (13.1)       76 (11.2)         15 (8.8)        0.02

   Elective surgery                                    28 (14.3)       160 (15.7)        159 (19.5)       130 (19.1)        25 (14.7)       0.09

   Emergency surgery/trauma                            17 (8.7)        97 (9.5)          73 (9.0)         49 (7.2)          8 (4.7)         0.19

   No co-morbidity                                     58 (29.6)       285 (27.9)        227 (27.8)       170 (25.0)        38 (22.4)       0.33

   Any co-morbidity                                    138 (70.4)      735 (72.1)        589 (72.2)       510 (75.0)        132 (77.6)      

  Laboratory findings on day-1, mean (SD)                                                                                                   

   White blood count (×10^9^/L)                        16.1 (16.4)     16.1 (15.3)       16.5 (16.9)      17.9 (16.1)       16.0 (10.6)     0.20

   Creatinine (μmol/L)                                 164.3 (148.2)   195.3 (160.6)     207.7 (167.9)    221.7 (165.2)     242.3 (201.8)   \< 0.001

   Bicarbonate (mmol/L)                                19.4 (6.7)      19.1 (6.4)        18.8 (6.4)       19.0 (6.7)        20.1 (6.1)      0.32

   Bilirubin (μmol/L)                                  33.2 (54.4)     41.5 (76.3)       44.1 (92.5)      41.5 (68.1)       31.1 (76.0)     0.29

   Platelets (×10^9^/L)                                206.9 (140.5)   198.4 (156.6)     185.6 (133.3)    210.3 (140.6)     223.5 (132.2)   0.004

   International normalized ratio                      1.8 (1.2)       1.7 (1.1)         1.8 (1.1)        1.8 (1.4)         1.7 (1.3)       0.78

  Creatinine clearance (mL/minute), mean (SD)                                                                                               

   MDRD^b^equation                                     85.9 (148.2)    56.5 (49.3)       48.1 (40.6)      43.1 (36.0)       37.1 (27.6)     \< 0.001

   Cockcroft-Gault equation                            69.6 (98.6)     49.8 (41.3)       42.3 (34.3)      37.9 (29.9)       33.6 (22.7)     \< 0.001

  Source of infection, number (%)                                                                                                           

   Community acquired infection                        102 (52.0)      555 (54.4)        410 (50.3)       350 (51.5)        105 (61.8)      0.06

   Nosocomial infection                                94 (48.0)       465 (45.6)        406 (49.8)       330 (48.5)        65 (38.2)       

  Bacteremia, Number (%)                               68 (34.7)       361 (35.4)        289 (35.4)       266 (39.1)        48 (28.2)       0.10

  Organ failures on day-1, number (%)                                                                                                       

   Cardiovascular                                      196 (100)       1020 (100)        816 (100)        680 (100)         170 (100)       \*

   Renal                                               80 (40.8)       550 (53.9)        501 (61.4)       447 (65.7)        112 (65.9)      \< 0.001

   Respiratory                                         146 (74.5)      777 (76.2)        605 (74.1)       491 (72.2)        128 (75.3)      0.48

   Hematologic                                         56 (28.6)       261 (25.6)        241 (29.5)       163 (24.0)        29 (17.1)       0.006

   Metabolic                                           110 (56.1)      551 (54.0)        441 (54.0)       367 (54.0)        91 (53.5)       1.00

   Central nervous system                              47 (24.0)       289 (28.3)        210 (25.7)       168 (24.7)        45 (26.5)       0.44

   Hepatic                                             32 (16.3)       195 (19.1)        157 (19.2)       144 (21.2)        31 (18.2)       0.60

   Coagulation                                         89 (45.4)       454 (44.5)        350 (42.9)       284 (41.8)        69 (40.6)       0.70

  Country, number (%)                                                                                                                       

   Canada                                              147 (75.0)      813 (79.7)        655 (80.3)       548 (80.6)        130 (76.5)      0.15

   USA                                                 28 (14.3)       101 (9.9)         90 (11.0)        75 (11.0)         28 (16.5)       

   Saudi Arabia                                        21 (10.7)       106 (10.4)        71 (8.7)         57 (8.4)          12 (7.1)        

  Period, number (%)                                                                                                                        

   ≤ 1997                                              57 (29.1)       301 (29.5)        218 (26.7)       191 (28.1)        32 (18.8)       0.18

   1998 to 2000                                        72 (36.7)       378 (37.1)        292 (35.8)       235 (34.6)        67 (39.4)       

   2001 to 2002                                        57 (29.1)       296 (29.0)        265 (32.5)       207 (30.4)        62 (36.5)       

   ≥ 2003                                              10 (5.1)        45 (4.4)          41 (5.0)         47 (6.9)          9 (5.3)         
  ----------------------------------------------------------------------------------------------------------------------------------------------------

APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index;^a^Serum creatinine \> 1.5 upper limit of normal,

^a^Serum creatinine \> 1.5 upper limit of normal = Chronic renal failure

^b^MDRD: Modification of diet in renal disease

Microbiologic data and sites of infections
------------------------------------------

Obese and very obese patients were more likely to have Gram-positive infections. Very obese patients were more likely to have sepsis from skin and soft tissue infections and less from pneumonia (Table [2](#T2){ref-type="table"}). Table [3](#T3){ref-type="table"} shows the sepsis interventions and Table [4](#T4){ref-type="table"} shows the fluid and antibiotic dosage among the five groups of BMI.

###### 

Microbiologic and sites of infection among different groups of BMI

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Number (%)                                                               \< 18.50\      18.50 to 24.99\   25.0 to29.99\   30.0 to 39.99\   ≥ 40\          *P*value
                                                                           Number = 196   Number = 1,020    Number = 816    Number = 680     Number = 170   
  ------------------------------------------------------------------------ -------------- ----------------- --------------- ---------------- -------------- ----------
  Total culture negative                                                   49 (25.0)      270 (26.5)        242 (29.7)      204 (30.0)       53 (31.2)      0.28

  Total culture positive                                                   147 (75.0)     750 (73.5)        574 (70.3)      476 (70.0)       117 (68.8)     

  Gram-negative organisms                                                  72 (36.7)      384 (37.7)        281 (34.4)      230 (33.8)       45 (26.5)      0.05

   *Escherichia coli*                                                      23 (11.7)      163 (16.0)        115 (14.1)      97 (14.3)        19 (1.2)       0.32

   Klebsiella                                                              16 (8.2)       62 (6.1)          41 (5.0)        36 (5.3)         7 (4.1)        0.38

   *Pseudomonas aeruginosa*                                                13 (6.6)       68 (6.7)          48 (5.9)        28 (4.1)         8 (4.7)        0.23

   Enterobacter species                                                    5 (2.6)        27 (2.7)          21 (2.6)        25 (3.7)         1 (0.6)        0.25

   *Haemophilus influenzae*                                                6 (3.1)        12 (1.2)          10 (1.2)        8 (1.2)          3 (1.8)        0.29

   Acinetobacter species                                                   4 (2.0)        10 (1.0)          6 (0.8)         11 (1.6)         2 (1.2)        0.38

   Other Gram-negative bacilli                                             5 (2.6)        42 (4.1)          40 (4.9)        25 (3.7)         5 (2.9)        0.49

  Gram-positive organisms                                                  41 (20.9)      247 (24.2)        183 (22.4)      168 (24.7)       60 (35.3)      0.007

   *Staphylococcus aureus*                                                 19 (9.7)       110 (10.8)        81 (9.9)        71 (10.4)        22 (12.9)      0.81

   *Streptococcus pneumonia*                                               9 (4.6)        60 (5.9)          37 (4.5)        37 (5.4)         8 (4.7)        0.74

   *Streptococci faecalis*                                                 4 (2.0)        19 (1.9)          17 (2.1)        17 (2.5)         6 (3.5)        0.68

   *Streptococcus faecium*                                                 2 (1.0)        11 (1.1)          8 (1.0)         4 (0.6)          3 (1.8)        0.69

   Group A streptococcus species                                           2 (1.0)        18 (1.8)          17 (2.1)        14 (2.1)         10 (5.9)       0.01

   Other β-hemolytic streptococci                                          3 (1.5)        12 (1.2)          10 (1.2)        13 (1.9)         8 (4.7)        0.01

   Other Gram-positive bacilli                                             2 (1.0)        17 (1.7)          13 (1.6)        12 (1.8)         3 (1.8)        0.97

  Fungi/Yeast                                                              20 (10.2)      77 (7.6)          84 (10.3)       62 (9.1)         8 (4.7)        0.08

   *Candida albicans*                                                      11 (5.6)       44 (4.3)          50 (6.1)        37 (5.4)         7 (4.1)        0.46

   Other candida/yeast                                                     9 (4.6)        33 (3.2)          34 (4.2)        25 (3.7)         1 (0.6)        0.18

  Anaerobes                                                                10 (5.1)       26 (2.6)          17 (2.1)        14 (2.1)         4 (2.4)        0.15

  Other organisms                                                          4 (2.0)        16 (1.6)          9 (1.1)         2 (0.3)          0              0.04

  Site of infection                                                                                                                                         

  Lung                                                                     95 (48.5)      445 (43.6)        301 (36.9)      226 (33.2)       53 (31.2)      \< 0.001

   Pneumonia                                                               91 (46.4)      435 (42.7)        296 (36.3)      223 (32.8)       51 (30.0)      0.45

   Empyema                                                                 4 (2.0)        10 (1.0)          5 (0.6)         3 (0.4)          2 (1.2)        0.22

  Intraabdominal                                                           53 (27.0)      299 (29.3)        268 (32.8)      228 (33.5)       53 (31.2)      0.20

   Intraabdominal abscess                                                  5 (2.6)        23 (2.3)          23 (2.8)        28 (4.1)         8 (4.7)        0.15

   Ascending Cholangitis                                                   2 (1.0)        23 (2.3)          14 (1.7)        13 (1.9)         0              0.28

   Cholecystitis                                                           1 (0.5)        9 (0.9)           14 (1.7)        12 (1.8)         1 (0.6)        0.26

   Ischemic bowel/bowel infarction                                         7 (3.6)        48 (4.7)          51 (6.3)        35 (5.2)         5 (2.9)        0.27

   Viscous bowel perforation                                               21 (10.7)      104 (10.2)        104 (12.8)      66 (9.7)         20 (11.8)      0.34

   Spontaneous bacterial peritonitis                                       3 (1.5)        31 (3.0)          14 (1.7)        17 (2.5)         1 (0.6)        0.16

   *Clostridium difficile*enterocolitis/toxic megacolon                    7 (3.6)        25 (2.5)          18 (2.2)        12 (1.8)         2 (1.2)        0.49

   Infected pancreatic necrosis                                            0              4 (0.4)           11 (1.4)        16 (2.4)         3 (1.8)        0.002

   Others                                                                  7 (3.6)        32 (3.1)          19 (2.3)        29 (4.3)         13 (7.7)       0.009

  Skin and soft tissue                                                     14 (7.1)       69 (6.8)          72 (8.8)        79 (11.6)        37 (21.8)      \< 0.001

   Cellulitis                                                              2 (1.0)        7 (0.7)           11 (1.4)        19 (2.8)         12 (7.1)       \< 0.001

   Necrotizing soft tissue infections                                      5 (2.6)        20 (2.0)          16 (2.0)        23 (3.4)         12 (7.1)       0.001

   Others                                                                  7 (3.6)        42 (4.1)          45 (5.5)        37 (5.4)         13 (7.7)       0.22

  Genitourinary                                                            17 (8.7)       92 (9.0)          80 (9.8)        70 (10.3)        18 (10.6)      0.88

  Intravascular catheter infection                                         8 (4.1)        38 (3.7)          29 (3.6)        36 (5.3)         6 (3.5)        0.46

  Primary bloodstream infection (bacteremia without identifiable source)   8 (4.1)        49 (4.8)          44 (5.4)        37 (5.4)         7 (4.1)        0.87

  Systemically disseminated infection (including yeast and tuberculosis)   6 (3.1)        29 (2.8)          26 (3.2)        18 (2.7)         5 (2.9)        0.98

  Septic arthritis                                                         0              5 (0.5)           7 (0.9)         7 (1.0)          6 (3.5)        0.002
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index.

###### 

Sepsis interventions related to septic shock among the five groups of BMI

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                    \< 18.50\      18.50 to 24.99\   25.0 to 29.99\   30.0 to 39.99\   ≥ 40\          *P*value
                                                              Number = 196   Umber = 1,020     Number = 816     Number = 680     Number = 170   
  ----------------------------------------------------------- -------------- ----------------- ---------------- ---------------- -------------- ----------
  Vasopressors used, Number (%)                                                                                                                 

   Dopamine                                                   117 (59.7)     594 (58.2)        465 (57.0)       408 (60.0)       91 (53.5)      0.54

   Norepinephrine                                             122 (62.2)     566 (55.5)        480 (58.8)       362 (53.2)       86 (50.6)      0.04

   Phenylephrine                                              58 (29.6)      336 (32.9)        255 (31.3)       219 (32.2)       48 (28.2)      0.70

   Epinephrine                                                12 (6.1)       45 (4.4)          41 (5.0)         31 (4.6)         15 (8.8)       0.15

   Dobutamine                                                 16 (8.2)       98 (9.6)          84 (10.3)        75 (11.0)        18 (10.6)      0.77

  Vasopressor dose - at six hours, mean (SD)                                                                                                    

   Dopamine (μcg/kg/minute)                                   7.7 (7.3)      6.7 (4.9)         6.5 (4.7)        6.4 (4.3)        6.2 (5.1)      0.22

   Norepinephrine (μcg/kg/minute)                             0.39 (0.41)    0.37 (0.60)       0.33 (0.43)      0.30 (0.47)      0.18 (0.18)    0.05

   Phenylephrine (μcg/kg/minute)                              3.4 (4.1)      2.2 (2.1)         2.1 (2.3)        2.0 (2.4)        1.2 (1.4)      0.003

   Epinephrine (μcg/kg/minute)                                0.85 (0.61)    0.30 (0.26)       0.33 (0.73)      0.18 (0.12)      0.21 (0.18)    0.04

   Dobutamine (μcg/kg/minute)                                 5.1 (1.7)      4.4 (2.5)         4.7 (2.9)        4.0 (2.8)        4.4 (2.5)      0.82

  Sepsis specific therapy                                                                                                                       

   Activated protein C, number (%)                            9 (4.6)        36 (3.5)          29 (3.6)         42 (6.2)         13 (7.7)       0.01

   Low-dose steroids, number (%)                              73 (37.2)      305 (29.9)        256 (31.4)       222 (32.7)       46 (27.1)      0.19

   Inappropriate antimicrobials therapy, number (%)           46 (23.5)      188 (18.4)        160 (19.6)       120 (17.7)       31 (18.2)      0.43

   Single versus combined antimicrobial therapy, number (%)   142 (72.5)     711 (69.7)        568 (69.6)       456 (67.1)       118 (69.4)     0.62

   Delay in antimicrobial therapy, mean (SD)                  17.8 (30.3)    13.9 (24.0)       15.1 (26.0)      12.6 (18.8)      16.7 (29.9)    0.12

  Others                                                                                                                                        

   Pulmonary artery catheter, number (%)                      91 (46.4)      513 (50.3)        428 (52.5)       386 (56.8)       89 (52.4)      0.04

   Pulmonary capillary wedge pressure, (mmHG), mean (SD)      15.0 (5.2)     16.5 (6.1)        17.6 (6.1)       18.6 (6.4)       20.5 (6.7)     \< 0.001

   Cardiac output (L/minute), mean (SD)                       6.4 (2.8)      7.1 (3.2)         7.6 (3.2)        7.7 (3.4)        8.7 (3.5)      \< 0.001

   Cardiac index(L/minute/m^2^), mean (SD)                    4.1 (1.7)      4.1 (1.7)         4.0 (1.6)        3.8 (1.5)        3.9 (1.5)      0.11
  --------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index.

###### 

Fluid and antibiotic dosage among different groups of BMI

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Intervention**^**a**^\                                               \< 18.50\            18.50 to 4.99\        25.0 to 29.99\        30.0 to 39.99\        ≥ 40\                 *P*value   **Adjusted *P*value**^**b**^   Adjusted\
  mean (SD)                                                              Number = 196         Number = 1,020        Number = 816          Number = 680          Number = 170                                                    ***P*value**^**c**^
  -------------------------- ------------------------------------------- -------------------- --------------------- --------------------- --------------------- --------------------- ---------- ------------------------------ ---------------------
  Crystalloid                Number = 1,506 (52.3%)                      Number = 96 (49.0)   Number = 537 (52.6)   Number = 439 (53.8)   Number = 346 (50.9)   Number = 88 (51.8)                                              

                             Total (ml)                                  2,580.3 (1,874.9)    2,690.0 (2,050.2)     2,861.7 (2,445.1)     2,537.4 (2,032.0)     2,602.3 (1,919.1)     0.30       0.76                           0.59

                             Dose per kg of actual body weight (ml/kg)   55.0 (40.1)          43.2 (33.4)           37.1 (30.8)           27.7 (22.0)           21.4 (16.8)           \< 0.001   \< 0.001                       \< 0.001

  Colloid                    Number = 1,506 (52.3%)                      Number = 96 (49.0)   Number = 537 (52.6)   Number = 439 (53.8)   Number = 346 (50.9)   Number = 88 (51.8)                                              

                             Total (ml)                                  656.8 (864.8)        509.8 (781.0)         593.5 (788.7)         705.5 (2,824.5)       538.9 (939.8)         0.44       0.79                           0.31

                             Dose per kg of actual body weight (ml/kg)   14.3 (19.3)          8.2 (12.7)            7.7 (10.2)            8.5 (44.2)            4.3 (7.2)             0.06       0.02                           \< 0.001

  Packed red blood cell      Number = 94 (3.3%)                          Number = 5 (2.6)     Number = 29 (2.8)     Number = 31(3.8)      Number = 24 (3.5)     Number = 5 (2.9)                                                

                             Total (ml)                                  462.0 (180.7)        601.0 (630.3)         522.5 (243.2)         502.0 (250.0)         961.2 (781.5)         0.26       0.68                           0.79

                             Dose per kg of actual body weight (ml/kg)   9.6 (4.1)            9.7 (10.8)            6.8 (3.1)             5.4 (3.0)             7.3 (5.5)             0.18       0.02                           0.53

  Fresh frozen plasma        Number 70 (2.4%)                            Number = 4 (2.0)     Number = 22 (2.2)     Number = 21(2.6)      Number = 18 (2.6)     Number = 5 (2.9)                                                

                             Total (ml)                                  737.5 (715.7)        498.7 (224.4)         600.0 (336.9)         526.8 (333.1)         1,260.0 (1,34.9)      0.01       0.005                          0.02

                             Dose per kg of actual body weight (ml/kg)   18.9 (20.8)          8.2 (4.4)             7.8 (4.7)             5.8 (3.7)             10.4 (8.4)            0.01       0.77                           0.62

  Piperacillin/tazo-bactam   Number = 564 (19.6%)                        Number = 46 (23.5)   Number = 214 (21.0)   Number = 145 (17.8)   Number = 129 (19.0)   Number = 30 (17.6)                                              

                             Total dose (mg)                             10,214.7 (3,216.3)   10,714.8 (3,155.2)    11,005.3 (3,074.6)    10,754.8 (3,264.7)    10,766.7 (2,699.9)    0.68       0.06                           

                             Dose per kg of dosing body weight           183.5 (66.7)         174.8 (59.9)          168.3 (56.1)          161.0 (59.9)          133.2 (40.2)          0.001      \< 0.001                       

  Cefotaxime                 Number = 772 (26.8%)                        Number = 51 (26.0)   Number = 297 (29.1)   Number = 212 (26.0)   Number = 173 (25.4)   Number = 39 (22.9)                                              

                             Total dose (mg)                             3,549.0 (1,932.0)    3,477.8 (1,821.8)     3,787.7 (1,857.4)     3,359.8 (1,531.0)     4,256.4 (2,220.9)     0.02       0.006                          

                             Dose per kg of dosing body weight           62.1 (38.5)          56.5 (31.6)           57.2 (28.7)           49.7 (24.4)           53.5 (30.2)           0.04       0.32                           

  Imipenem                   Number = 242 (8.4%)                         Number = 15 (7.7)    Number = 79 (7.7)     Number = 75 (9.2)     Number = 56 (8.2)     Number = 17 (10.0)                                              

                             Total dose (mg)                             1,566.7 (457.7)      1,665.2 (597.5)       1,693.3 (700.6)       1,705.4 (796.5)       1,426.5 (584.7)       0.60       0.36                           

                             Dose per kg of dosing body weight           25.9 (9.0)           27.0 (9.9)            24.9 (10.3)           24.2 (13.1)           7.3 (54.6)            0.002      \< 0.001                       

  Gentamycin                 Number = 511 (17.7%)                        Number = 33 (16.8)   Number = 184 (18.0)   Number = 149 (18.3)   Number = 122 (17.9)   Number = 23 (13.5)                                              

                             Total dose (mg)                             173.3 (82.4)         219.9 (241.4)         256.7 (229.4)         239.4 (118.3)         262.0 (121.9)         0.18       0.01                           

                             Dose per kg of dosing body weight           3.2 (1.5)            3.6 (4.0)             3.8 (3.2)             3.3 (1.7)             3.2 (1.6)             0.63       0.96                           

  Meropenem                  Number = 277 (9.6%)                         Number = 19 (9.7)    Number = 83 (8.1)     Number = 85 (10.4)    Number = 70 (10.3)    Number = 20 (11.8)                                              

                             Total dose (mg)                             2,342.1 (1,179.1)    1,807.2 (791.8)       1,865.9 (990.6)       1,678.6 (920.9)       2,050.0 (916.2)       0.07       0.75                           

                             Dose per kg of dosing body weight           40.7 (19.4)          29.8 (15.0)           28.8 (15.7)           25.0 (15.5)           26.1 (11.3)           0.003      0.01                           

  Levofloxacin               Number = 301 (10.4%)                        Number = 28 (14.3)   Number = 110 (10.8)   Number = 81 (9.9)     Number = 62 (9.1)     Number = 20 (11.8)                                              

                             Total dose (mg)                             426.8 (118.2)        489.8 (164.3)         488.0 (205.8)         441.5 (251.8)         462.5 (91.6)          0.32       0.82                           

                             Dose per kg of dosing body weight           8.0 (2.5)            8.0 (3.1)             7.1 (2.8)             6.2 (4.4)             5.3 (1.3)             \< 0.001   \< 0.001                       

  Vancomycin                 Number = 771 (26.8%)                        Number = 53 (27.0)   Number = 261(25.6)    Number = 209 (25.6)   Number = 194 (28.5)   Number = 54 (32.1)                                              

                             Total dose (mg)                             1,292.5 (521.6)      1,421.2 (630.3)       1,380.4 (578.4)       1,353.1 (623.0)       1,441.4 (680.6)       0.54       0.20                           

                             Dose per kg of dosing body weight           28.5 (13.7)          22.9 (11.2)           17.9 (7.6)            14.8 (7.2)            11.3 (5.8)            \< 0.001   \< 0.001                       

  Ciprofloxacin              Number = 634 (22.0%)                        Number = 39 (19.9)   Number = 218 (21.4)   Number = 186 (22.8)   Number = 165 (24.3)   Number = 26 (15.3)                                              

                             Total dose (mg)                             682.9 (280.3)        674.4 (237.0)         671.4 (255.8)         670.3 (363.1)         682.7 (210.2)         1.0        0.13                           

                             Dose per kg of dosing body weight           13.0 (5.2)           10.9 (4.4)            10.1 (4.1)            9.1 (5.0)             7.6 (2.6)             \< 0.001   \< 0.001                       

  Ampicillin                 Number = 340 (11.8%)                        Number = 19 (9.7)    Number = 122 (12.0)   Number = 115 (14.1)   Number = 70 (10.3)    Number = 14 (8.2)                                               

                             Total dose (mg)                             4,106.6 (1,788.6)    4,002.3 (1,940.8)     4,326.1 (2,019.7)     4,072.1 (1,64.0)      5,071.4 (2,302.7)     0.31       0.01                           

                             Dose per kg of dosing body weight           71.8 (38.4)          64.8 (32.2)           66.5 (33.0)           61.3 (31.0)           67.0 (36.3)           0.74       0.85                           

  Amphotericin B             Number = 102 (3.5%)                         Number = 5 (2.6)     Number = 34 (3.3)     Number = 36 (0.4)     Number = 25 (3.7)     Number = 2 (1.2)                                                

                             Total dose (mg)                             3,897.2 (4,330.8)    5,531.1 (3,998.5)     6,866.2 (5,977.6)     5,079.2 (4,933.2)     10,520.0 (10,521.7)   0.35       0.53                           

                             Dose per kg of dosing body weight           85.4 (91.9)          84.9 (59.7)           90.9 (80.2)           54.3 (52.4)           83.5 (86.7)           0.33       0.15                           

  Ceftazidime                Number = 292 (10.1%)                        Number = 25 (1.3)    Number = 106 (10.4)   Number = 89 (10.9)    Number = 58 (8.5)     Number = 14 (8.2)                                               

                             Total dose (mg)                             2,710.0 (1,154.0)    3,547.2 (1,867.7)     2,995.3 (1,691.5)     3,025.9 (1,590.6)     3,285.7 (1,683.8)     0.08       0.10                           

                             Dose per kg of dosing body weight           47.2 (18.3)          57.5 (30.7)           46.9 (28.0)           43.9 (23.6)           42.7 (17.7)           0.01       0.48                           

  Ceftriaxone                Number = 232 (8.0%)                         Number = 12 (6.1)    Number = 77 (7.5)     Number = 67 (7.6)     Number = 58 (8.5)     Number = 18 (10.6)                                              

                             Total dose (mg)                             1,666.7 (492.4)      1,655.8 (1,052.1)     1,776.1 (884.6)       1,672.4 (943.8)       1,611.1 (607.7)       0.93       0.77                           

                             Dose per kg of dosing body weight           31.9 (10.2)          26.1 (14.4)           27.5 (12.7)           24.6 (13.7)           21.5 (8.7)            0.20       0.02                           

  Cefuroxime                 Number = 772 (26.8%)                        Number = 19 (9.7)    Number = 74 (7.3)     Number = 68 (8.3)     Number = 55 (8.1)     Number = 11(6.5)                                                

                             Total dose (mg)                             2,578.9 (920.6)      2,171.8 (1,063.2)     2,216.9 (808.0)       2,386.4 (842.7)       2,181.8 (975.3)       0.39       0.68                           

                             Dose per kg of dosing body weight           45.3 (18.9)          35.1 (17.0)           32.7 (12.9)           34.6 (15.0)           26.7 (12.1)           0.01       0.02                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**^a^**Crystalloid, colloid, crystalloid equivalent volume, red blood cell and fresh frozen plasma for first six hours. All others for day 1. ^b^Adjusted for creatinine clearance. ^c^Adjusted for creatinine clearance and pulmonary capillary wedge pressure. BMI, body mass index.

Outcomes
--------

Crude hospital mortality, ICU mortality, hospital LOS and ICU LOS differed among the BMI groups (Table [5](#T5){ref-type="table"}). Compared with patients with normal BMI, the crude OR for obese patients was 0.80, 95% CI 0.66 to 0.97 and for the morbidly obese was 0.61, 95% CI 0.44 to 0.85. After adjustment for baseline characteristics (model 1) and for baseline characteristics and sepsis interventions (model 2), the OR and CI became non-significant statistically (Figure [1](#F1){ref-type="fig"}).

###### 

Outcomes among different groups of BMI

  ---------------------------------------------------------------------------------------------------------------------------------
                                       \< 18.50\      18.50 to 24.99\   25.0 to 29.99\   30.0 to 39.99\   ≥ 40\          *P*value
                                       Number = 196   Number = 1,020    Number = 816     Number = 680     Number = 170   
  ------------------------------------ -------------- ----------------- ---------------- ---------------- -------------- ----------
  Hospital mortality, number (%)       121 (61.7)     580 (56.9)        444 (54.4)       349 (51.3)       76 (44.7)      0.003

  ICU mortality, number (%)            102 (52.0)     451 (44.2)        335 (41.1)       265 (39.0)       57 (33.5)      0.001

  ICU length of stay, mean (SD)        9.9 (9.4)      10.5 (12.5)       11.4 (14.7)      11.2 (14.3)      12.2 (12.7)    0.30

  Hospital length of stay, mean (SD)   25.1 (33.6)    25.1 (31.8)       27.8 (35.2)      26.5 (34.8)      34.3 (44.2)    0.02
  ---------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index.

![**Odds ratios and confidence intervals of hospital mortality among different BMI groups in multivariate logistic regression analysis**. **Panel A**: Crude analysis. **Panel B**: Adjusted analysis to baseline characteristics (model 1). **Panel C**: Adjusted analysis to baseline characteristics and sepsis interventions (model 2). BMI, body mass index.](cc12680-1){#F1}

Discussion
==========

Our study found that: 1) the BMI of patients with septic shock varies considerably; 2) septic shock in the obese and very obese differs in the presentation, sites of infection and microbiology compared to non-obese patients; 3) sepsis interventions, especially the volume of resuscitation fluids and doses of antibiotics, do not appear to take into consideration the variations in BMI, leading to considerable differences in weight-adjusted doses; and 4) crude hospital mortality of obese and morbidly obese patients with septic shock was lower than normal weight patients, but this was explained at least in part by differences in baseline characteristics and sepsis interventions.

Our study revealed that obese and morbidly patients with septic shock display some differences in their clinical presentation, site and type of infection. Indeed, underweight and very obese patients with septic shock had fewer hemodynamic disturbances and, thus, required lower doses of vasopressors (expressed as mcg/kg/minute for norepinephrine and epinephrine) than normal weight patients, although with comparable APACHE II scores. Further, the source of infection in obese patients was more likely to be related to skin and soft tissue infections and less likely to be related to pneumonia with predominantly Gram-positive microorganisms.

Our study examined the influence of weight and BMI on sepsis interventions. We observed that similar volumes of resuscitation fluids and similar total doses of antimicrobials were administered regardless of BMI. This translated to lower volume/kg and dose/kg in the obese and very obese patients compared to the normal BMI patients even after adjustment for wedge pressure and creatinine clearance. For example, we found that very obese patients received 27.7 ± 22.0 ml/kg crystalloid volume in the first six hours compared to 55.0 ± 40.1 ml/kg in the underweight group. This probably reflects routine clinical practice which is not weight-based as physicians often administer a standard bolus of 1,000 ml crystalloid or 300 to 500 ml colloid, irrespective of body weight. Unlike pediatricians, physicians caring for adult patients do not routinely take weight and height into consideration in decision-making. The issue is further confounded by the large number of correction formulae for weight adjustment (actual, adjusted, ideal, predicted, antimicrobial dosing body weights) that are mostly not based on clinical outcome studies, leaving the bedside practitioner unclear about the best approach \[[@B6],[@B29]\]. Additionally, it remains unclear whether dosing vasopressors, such as norepinephrine and epinephrine, based on weight (as mcg/kg/minute) is superior to non-weight based dosing (as mcg/minute) as both approaches are seen in practice and in clinical trials \[[@B30],[@B31]\].

Our study shows that crude hospital mortality of obese and very obese patients with septic shock was lower than normal weight patients. Because the effect became insignificant after adjustment, we believe that the observed differences in mortality were explained partially by baseline characteristics and sepsis interventions. The effect of obesity on outcome of critically ill patients has been a subject of considerable debate \[[@B32]\]. Two meta-analyses revealed discordant results, with one showing no difference in mortality between obese and normal-weight critically ill adults \[[@B33]\] and another demonstrating a trend toward decreased risk of mortality in overweight and obese patients compared with those with normal BMI \[[@B11]\]. In septic shock, a retrospective study of 301 patients with septic shock found that overweight and obese patients had lower mortality than those with normal weight \[[@B18]\].

Despite this supportive evidence, how a condition that increases cause-specific mortality, such as ischemic heart disease, diabetes, cancer and respiratory diseases, can be neutral or even provides a survival advantage during critical illness, remains perplexing. Several possible explanations exist. First, epidemiologic and statistical reasons may explain the association. The lower observed mortality might be related to lead-time bias and to the earlier age in the very obese septic patients. Additionally, the obese and morbidly obese patients may be \'healthier\' than the normal BMI patients. Obese patients displayed more diabetes and related complications, while the normal weight had more devastating illnesses, including hematologic and solid organ malignancies. Therefore, the observed differences in outcome may be related to worse outcome in the normal weight patients and not to \'better\' outcome in the obese. Additionally, septic shock in the obese and very obese may be less severe as shown by the lower vasopressor doses. The calibration of APACHE II in morbidly obese patients has to be validated, because several of its components, such as oxygenation, may be altered due to obesity and not to the acute illness. Finally, although we adjusted for several co-morbidities, residual confounding cannot be ruled out.

Second, our study identified differences in sepsis interventions as one of the potential explanations for this apparent paradox. Several studies have highlighted disparities in care provided to patients in the obese and very obese groups compared with patients in other categories \[[@B34],[@B35]\]. At present, there is no strong evidence to support whether a weight-based approach for fluid resuscitation, antibiotic or vasopressor dosing is superior to the non-weight-based approach. Our study shows clearly that obese patients received a lower amount of resuscitation fluids and dose of antibiotics based on weight. Although one cannot establish a causal relationship with mortality, emerging evidence suggests that over-resuscitation may have detrimental effects \[[@B36],[@B37]\]. Therefore, it is appealing to speculate that this may have contributed to the higher mortality in both lower and normal BMI patients, thus making obesity appear neutral or protective. Further, our study did not examine other important sepsis interventions, such as tidal volume \[[@B38],[@B39]\] and doses of other medications, all of which deserve further study.

Third, the observed association of obesity with lower mortality may be related to true biological reasons. One explanation is an underlying difference in metabolic and immune response to acute illness \[[@B40]\]. Obesity activates many inflammatory pathways that deregulate physiological responses, which maintain metabolic homeostasis including insulin and leptin sensitivity. One can speculate that a superimposed episode of acute inflammation triggered by sepsis on top of the chronic inflammation may induce a different immune response than in naïve patients. A second possible explanation has been variations in vital signs leading to perception of higher severity of illness \[[@B8]\]. However, in our cohort of patients with septic shock, we found that very obese patients had a slightly lower heart rate and respiratory rate and higher blood pressure and temperature, which may be related to a different response but could also be simply related to less severe shock in contrast to what has been suggested by Martino *et al.*\[[@B8]\].

It is important to note that these findings apply to the individual episode of septic shock only. Once septic shock sets in, our data suggest that patients in the obese and very obese groups may have outcomes that are similar or not worse than those in other groups. We did not capture data about the association between obesity and predisposition to sepsis in the general population. However, considering the younger age of very obese patients in the septic population, one may question whether obesity actually increases the risk for septic shock. This point and the life-long consequences of septic shock on the obese patients need to be studied in a population-based cohort.

Our study should be interpreted in light of its strengths and limitations. To our knowledge, this is the largest study to date specifically addressing the impact of obesity on outcomes among patients with septic shock. The inclusion of patients from 28 ICUs based in three geographic regions lends the study wide generalizability. In terms of limitations, the findings only highlight associations and cause-effect relationships cannot be inferred. We used the weight and height as documented in the medical records, the precision of which could not be verified. The availability of BMI data on only one third of patients may have led to selection bias. However, the comparison between excluded and included patients showed minor differences that are unlikely to explain the magnitude of the observed differences among BMI groups. Furthermore, this lack of data may represent perception bias as healthcare workers are more likely to measure height and weight in extreme groups of BMI. Our study did not address the possibility of measurement bias arising from systematic errors in measuring weight, height and blood pressure across different BMI groups. We adjusted for severity of illness as measured by APACHE II and other possible confounders; we cannot rule out residual confounding especially considering the large number of possible factors that may influence outcome in acutely ill patients. Finally, we do not have data on the sagittal abdominal diameter, which has been shown to be an independent risk factor of death in critically ill patients \[[@B41]\].

Conclusions
===========

In the septic shock population, we observed the obesity paradox (lower mortality in the obese) reported in other populations. This may be related in part to differences in patient characteristics. However, the true paradox may lie in the variations in the sepsis interventions, such as the administration of resuscitation fluids and antimicrobial therapy. Further studies are warranted to examine whether a weight-based approach to common therapeutic interventions in septic shock influences outcome.

Key messages
============

• The presentation, microbiology and organ failures are different among obese patients compared to the non-obese.

• Very obese patients presented at an early age to the ICU with septic shock and had more underlying chronic co-morbidities compared to non-obese patients.

• There is a considerable variation in the volume of fluid resuscitation per kg and antibiotic dosing among different BMI groups.

• The obesity paradox (lower mortality in the obese) as reported in other populations was observed in septic shock patients as well.

• The true paradox may lie in the variations in the sepsis interventions, such as the administration of resuscitation fluids.
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